Background: African swine fever virus (ASFV) is the unique member of the Asfarviridae family and Asfivirus genus. It is an enveloped double-stranded DNA arbovirus that replicates in the cell cytoplasm, similar to poxviruses. There is no vaccine and no treatment available to control this virus. Methods: We describe the use of small interfering RNA (siRNA) targeting the A151R and VP72 (B646L) genes to control the ASFV replication in vitro. Results: Results suggest that siRNA targeting the A151R and VP72 genes can reduce both the virus replication and its levels of messenger RNA transcripts. The reduction was up to 4 log 10 copies on the virus titre and up to 3 log 10 copies on virus RNA transcripts levels. The combination of multiple siRNA did not improve the antiviral effect significantly, compared with use of individual siRNAs. Conclusions: The function of the A151R gene product in the virus replication cycle is yet unclear, but is essential. We also demonstrate that it is possible to inhibit, using small interfering RNA, a virus that replicates exclusively in the cell cytoplasm in specific viral factories.
African swine fever virus (ASFV) is a contagious and lethal viral disease of domestic pigs and European wild boars caused by a virus of the Asfivirus genus, the unique member of the Asfarviridae family [1, 2] . This virus is also an arbovirus, as soft ticks are biological vectors that can be infected and transmit the disease through biting. ASFV pathogenesis varies from a generalized haemorrhagic fever to asymptomatic infections, depending on viral and host factors [3] . The mortality in severe cases in domestic pigs and European wild boars can be as high as 100%. There is currently no vaccine and no treatment available against this disease. The disease is endemic in the African continent and Sardinia. Recently, ASFV was introduced in Caucasus [4] .
ASFV is a large double-stranded DNA virus encoding >150 proteins. It replicates in the cell cytoplasm [5] , similar to poxviruses. The virus is known to modulate the immune response in the infected host by expressing several proteins that act as virulence factors. It has been previously shown that ASFV can be attenuated by deleting genes involved in virulence [6] [7] [8] [9] . In a strategy to produce an attenuated ASFV vaccine by deletion, our group identified a region within the left variable part of the genome that includes virulence genes, such as A224L, expressing an anti-apoptotic protein, and A238L, expressing a nuclear factor-κB antagonist [10] [11] [12] [13] . The A151R product function is unclear. To investigate whether this A151R gene is essential for virus replication, its expression was repressed using an RNA interference approach. Another gene (B646L) encoding the virus capsid protein VP72 was included in the study as a control of small interfering RNA (siRNA) repression, as it is likely that this gene is essential in the virus replication cycle.
RNA interference was first described in nematodes [14] , but was later confirmed to be present in most eukaryotic cells [15] [16] [17] [18] . It acts in the cell cytoplasm through siRNAs of 21-23 nucleotides that specifically bind to a messenger RNA (mRNA), triggering cleavage of the mRNA by an RNA-induced silencing complex (RISC) and resulting in the post-transcriptional downregulation of the targeted gene [18] [19] [20] . In this study, we show that A151R and VP72 (B646L) mRNA are repressed by the introduction of complementary siRNAs, and that the down-regulation negatively affects viral replication. 
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Methods
The Spanish Vero-adapted strain of ASFV (Badajoz 1971, BA71V [21] ) was kindly provided by the Centro de Biologia Molecular (Madrid, Spain). A virus stock was prepared in Vero cells maintained at 37°C and 5% CO 2 in Eagle's minimal essential medium (EMEM) supplemented with 10% fetal bovine serum (FBS; Eurobio, Courtaboeuf, France) and 2 mM l-glutamin (Gibco, Life Technology, Paisley, UK). The virus stock was titrated as previously described [22] and expressed in median tissue culture infective dose (TCID 50 )/ml. The infections of Vero cells for the RNA interference studies were done at multiplicities of infection (MOI) of 0.1 or 0.01 TCID 50 , respectively.
The nucleotide sequences of A151R and VP72 genes of BA71V strain (GenBank/EMBL accession number ASU18466 [21] ) were first verified by direct sequencing of the virus stock. Specific primers corresponding to the ends of each gene were used to amplify the genes by PCR (Table 1) . The amplified products were purified and sent to GATC (Konstanz, Germany) for direct sequencing. Eleven double-stranded 21-nucleotide RNAs were designed by Cenix algorithm (Ambion/Applied Biosystems, Cergy-Pontoise, France) based on the verified sequences. Three RNAs, siRNA-A151R_1, _2 and _3, were designed to target the A151R. An additional set of eight RNAs, named siRNA-VP72_1 to _8 were designed against the VP72 gene. An irrelevant siRNA targeting the GAPDH gene (siRNA-GAPDH; Silencer™ GAPDH siRNA human control number 4605; Ambion/Applied Biosystems) was used as a negative control in all inhibition experiments. An additional irrelevant siRNA (siRNA-NPPR1) targeting the nucleoprotein gene of an animal morbillivirus was included in the initial tests; this siRNA represses the morbillivirus replication [23] and was selected because it has a base composition that is similar to siRNA-A151R_3 (A6, U5, G5 and C3). Because no differences were seen between siRNA-GAPDH and siRNA-NPPR1, only the former siRNA was kept as a control in all test repetitions, for practical and economical reasons. To verify the specificity of the siRNAs, sequences were queried against the BLAST database. For the most efficacious siRNA, nucleotide sequences were compared with ASFV sequences available in GenBank, in order to assess the conservation of the targeted regions. For the VP72 gene, a total of 58 sequences were retrieved in GenBank. A total of 9 A151R gene sequences were retrieved from GenBank, and sequences were generated in this study for an additional 10 For transfection assays, 10 5 Vero cells in 500 µl of EMEM supplemented with 10% FBS were seeded into a 24-well plate and incubated at 37°C. Different concentrations of siRNA were initially diluted in 100 µl of culture medium without serum and then adjusted to final concentrations of 6.25, 12.5, 25, 50 and 100 nM in 600 µl of transfection solution. An 8 µl aliquot of HiPerfect Transfectant reagent (Qiagen, Courtaboeuf, France) were added to the diluted siRNA and mixed by pippeting. The mix was incubated for 15 min at room temperature to allow the formation of transfection complexes, overlaid onto the cells and the cells were gently mixed to ensure uniform distribution of the complexes. Cells were further incubated with EMEM supplemented with 10% FBS for 6 h; the medium was then discarded and 1 ml of EMEM supplemented with 5% FBS was added. Unless otherwise stated, at 1 h or 24 h post-transfection, cells were infected with BA71V in 200 µl of serum-free EMEM. When the antiviral effect of siRNA was measured on virus titres and cytopathic effect (CPE), two virus loads were tested for each: 0.1 and 0.01 MOI. By contrast, when the antiviral effect was assessed through the quantification of mRNA, the virus challenge could not be >0.01 MOI, presumably because of RNA saturation that prevented the detection of any differences. At 1 h post-infection, cells were rinsed with 700 µl of EMEM to remove virus inoculum and 1 ml of EMEM supplemented with 5% FBS was added. In some assays, cells were not rinsed to test the effect of residual infectivity on the siRNA efficacy. A quantity of 800 µl of EMEM supplemented with 5% FBS was added to the virus inoculum. In all assays, cells were incubated for an extra period of 72 h. Controls consisted of non-transfected infected or transfected uninfected cells. Individual, as well as several combinations of siRNAs, were transfected. Combinations of siRNAs consisted of siRNA-A151R_1+2, siRNA-A151R_1+3, siRNA-A151R_2+3, siRNA-A151R_1+2+3, siRNA-A151R_2+VP72_8 and siR-NA-A151R_2+3+VP72_8. Dose effect was measured by transfecting cells with fourfold serial dilutions of siRNA starting at 100 nM.
CPEs were visualized by two different investigators using an inverted microscope. The two investigators had to characterize the importance of CPE by using a scale with four grades: 0 (no CPE), 33 (CPE≤33%), 66 (CPE>33% and ≤66%) and 100 (CPE>66%) as previously described [24] . The final CPE values were the averages of the two readers. This method was previously shown to give results with a comparable sensitivity to real-time PCR or flow cytometry [23, 24] . In addition, cells and supernatants harvested 72 h post-infection were kept at -70°C until used for virus titration or mRNA quantification. Infectious virus in cell supernatants was titrated using 10-fold serial dilutions inoculated onto Vero cells. The virus titre was expressed in TCID 50 /ml. For assays in which the virus inoculum was not discarded and cells not rinsed after infection, a control was included to measure the residual infectivity of virus inoculum after incubation for 3 days. This control consisted of 200 µl of virus inoculum and 800 µl EMEM supplemented with 5% FBS laid on a plastic well with no cells and titrated after 72 h of incubation at 37°C.
Total cellular RNA was extracted using the RNeasy Mini kit (Qiagen) according to the manufacturer's instructions. RNA was eluted in 50 µl of ultra-pure water and stored at -70°C for future use. To eliminate the presence of viral genomic DNA, 15 µl of RNA were treated by DNase I digestion reagent (TURBO DNAfree™ Kit number AM1907; Ambion/Applied Biosystems). The mix was incubated for 30 min at 37°C and DNase inactivated by the addition of the inactivation reagent solution. Reaction was incubated for 2 min at room temperature and mixed 3×, centrifuged 5 min at 10,000 rpm, and supernatant collected in a new tube for real-time reverse transcriptase PCR.
Quantification of RNA transcripts were carried out by quantitative real-time PCR using primers designed for A151R and VP72 genes (Primer3 software; Table 1 ). Specific complementary DNA for each of the genes was synthesized by reverse transcription at 50°C for 30 min, followed by PCR amplification in the same tube using 1 µl StrataScript Reverse Transcriptase (Stratagene, Amsterdam, the Netherlands), 2 µl of extracted RNA, 12.5 µl of SYBR Green Master mix (2×; Stratagene), 2.5 µl of each primer (initial concentration 1 µM) and up to 4.5 µl of water. Thermocycling was performed using an Mx3005P machine (Stratagene). The PCR cycling programme consisted of a denaturation for 10 min at 95°C, followed by 40 cycles of 30 s at 95°C, 1 min at 56°C and 30 s at 72°C for VP72 and 18S genes and 30 s at 95°C, 1 min at 58°C and 30 s at 72°C for the A151R gene. PCR amplification was followed by one cycle of dissociation of 1 min at 95°C, 30 s at 55°C and 30 s at 95°C.
To determine A151R and VP72 gene copy number, two standards were constructed by cloning the target genes into standard vector plasmids. Total DNA from 100 µl of BA71V supernatant was extracted with a GFX Genomic Blood DNA Column purification kit (GE Healthcare, Orsay, France) according to the manufacturer's protocol. PCR products of complete genes A151R (560 base pairs) and VP72 (2,277 base pairs) were amplified using 10 µl of BA71V DNA template, 0.5 µl of DNA polymerase in 25 µl of Premix C (FailSafe PCR System with PreMix Choice Kit; Epicentre, Tebu-Bio, Le Perray-en-Yveline, France) containing 1 µl at 25 pmol/µl of each couple of appropriate primers (Table 1 ) and 12.5 µl of water. Thermocycling was performed on an Applied Biosystems 2720 Thermal Cycler Instrument (Applied Biosystems, CergyPontoise, France). The PCR cycling programme consisted of a denaturation step for 4 min at 94°C followed by 25 cycles of 30 s at 95°C, and 30 s at 55°C, with a final extension step at 72°C for 45 s for the A151R gene and 2.5 min for the VP72 gene. All PCR products included a final extension step of 7 min at 72°C. Purified products were cloned in suitable vector plasmids yielding pCRBlunt-A151R and pSC-B-VP72. Standard curves were prepared using plasmids linearized with BamHI restriction enzymes and used to determine copy numbers.
The gene encoding the 18S ribosomal subunit was selected as a housekeeping gene to assess the quantity of total RNA extracted from each Vero cell preparation and to normalize the quantification of the other transcripts [25] . A standard consisting of five 10-fold serial dilutions of RNA extracted from 10 6 Vero cells was included in all PCR assays. The copy numbers of A151R and VP72 genes were then adjusted against the copy number of 18S RNA.
The statistical significances of the results were determined using the Student's t-test. P-values were calculated for all transfected cultures compared with the positive control of virus replication.
Results
Verified sequences of A151R and VP72 genes were submitted to Ambion/Applied Biosystems for design of 11 siRNAs using proprietary Cenix software. Cell cultures were transfected with the different siRNAs and the effect on viral replication measured. When transfected 24 h before virus infection, all siRNA targeting the A151R gene inhibited the virus replication at all concentrations tested (between 1 nM and 100 nM) with maximal efficacy achieved at 100 nM. At 100 nM, the CPE caused by virus replication could be reduced by 80% at MOI 0.1 and 90% at MOI 0.01 ( Figure 1 and Table 2 ). Increasing the concentration beyond 100 nM did not increase inhibition significantly. Concentration of siRNAs beyond 400 nM also induced cell toxicity (DK et al., data not shown).
A clear decrease of virus progeny was also observed with a reduction of virus titres >3 log 10 at MOI 0.1 and 0.01 compared with the positive control ( Figure 1 and Table 2 ). Results were further confirmed by real-time PCR on the corresponding gene transcripts for the tests at MOI 0.01. Levels of mRNA were reduced by 2 log 10 in the presence of the three siRNA targeting the A151R gene and siRNA-VP72_8 (Figure 1) . Interestingly, the three siRNAs against A151R mRNA not only repressed the expression of the A151R gene by 2 log 10 but also the expression of the late VP72 gene by 1.8 log 10 . Serial fourfold dilutions of siRNA-A151R_2 showed a dose relationship on antiviral effects (Figure 2) . The minimal effective dose of siRNA-A151R_2 was 0.39 nM resulting in a reduction of the virus titre by 1.2 log 10 .
CPE and virus titres were significantly decreased by 70% and between 2 to 3 log 10 values (P<0.02) by siRNA-VP72_7 and VP72_8, respectively. However, both siRNAs had more limited effects on the expression of VP72 mRNA (1-1.7 log 10 ) and A151R mRNA (1-1.3 log 10 ) compared with the levels of inhibition achieved by the siRNAs targeting A151R. The irrelevant siRNA-GAPDH and siRNA-NPPR1 (DK et al., data not shown), and siRNA-VP72_1, siRNA-VP72_2 and siRNA-VP72_5 had no effect on the CPE, virus titres or the expression of the two genes. The siRNA-VP72_3, siRNA-VP72_4 and siRNA-VP72_6 were considered to have only a marginal effect (Figure 1 ). The effects of siRNA-A151R_2 or siRNA-VP72_8 were not different, irrespective of whether the virus inoculum was removed or not after the initial infection (DK et al., data not shown). The virus was not removed in some trials in order to assess the residual contribution of the inoculum infectivity in the final virus titres. As mentioned in Methods, residual infectivity was determined by titration of the inoculum after 72 h at 37°C in the absence of cells. Interestingly, virus inoculums corresponding to MOI 0.1 and 0.01 when stored at 37°C for 3 days only decreased by 0.3 and 0.6 log 10 , respectively. Because the virus titres in cells treated with siRNA were always higher (>1 log 10 ) than the residual titre of the virus inoculum, we can conclude that none of our siRNAs could completely inhibit the virus replication.
When the most efficient siRNAs against the A151R and VP72 genes were delivered 1 or 24 h after virus infection at MOI 0.1, the inhibition of virus replication was marginal (DK et al., data not shown); however, when the inoculum was reduced to MOI 0.01, an inhibitory effect was observed irrespective of when infected cells were exposed to the siRNA ( Table 2) . As expected, the inhibition of CPE varied from 70% for siRNA against VP72 to 90% for siRNA-A151R_2 for cells infected 1 and 24 h after the siRNAs delivery. By contrast, the CPE was reduced by only 35-70% when the infection took place 24 and 1 h before the siRNA delivery. Similarly, the reduction of virus titres increased between 1.7 and 3.3 log 10 values when siRNAs were delivered 1 and 24 h before infection, whereas the reduction ranged between 0.1 and 2.5 log 10 values when siRNAs were delivered 24 and 1 h after infection (Table 2) .
In an attempt to increase the levels of inhibition, cells were transfected with a combination of siRNAs. At 100 nM, the combination of multiple siRNA that target different regions of the A151R gene or the two A151R and VP72 genes, increased the efficacy by only 0.2-0.9 log 10 values compared with the single siRNA-A151R_2 (Figure 3) . The increase was only significant for the combined siRNA-A151R_1+_2+_3, siRNA-A151R_2+VP72_8 and siRNA-A151R_2+_3+VP72_8 (P<0.05). Transfection of multiple siRNAs did not improve efficacy at lower concentrations compared with single siRNAs (Figure 2 ). In addition, the combination of siRNAs did not improve the antiviral effect when the delivery followed the virus infection (DK et al., data not shown).
To assess whether the genetic variations could possibly affect the efficacy of the siRNAs, the sequence of the most effective siRNA were compared with A151R gene sequences of 19 ASFV isolates. The analysis of the four targeted regions showed 91%, 65%, 50% and 40% conservation, for siRNA-VP72_8, siRNA-A151R_1, siRNA-A151R_3 and siRNA-A151R_2, respectively ( Table 3 ). The lowest conservation of the target sequence was observed for siRNA-A151R_2, the siRNA targeting the A151R gene that resulted in the most significant inhibition of virus replication.
Discussion
In this study, the transfection of cells with siRNAs targeting the A151R and VP72 genes resulted in the reduction of A151R and VP72 mRNA levels, CPE and virus titres. This demonstrates that the A151R protein is essential for virus replication. The function of the A151R gene product has not yet been fully characterized. The corresponding protein is expressed during both early and late stages of virus replication [26] . During the early stages of virus replication the protein Table 2 . Efficacy of five siRNAs when delivered at 100 nM at different time points before or after the virus infection
The effect was measured by virus titration in supernatants and messenger RNA quantification in cell cytoplasm by real-time reverse transcriptase PCR. Multiplicity of infection was equal to 0.01. Positive control (PC) is the virus BA71V alone. CPE, cytopathic effect; siRNA, small interfering RNA; TCID 50 , median tissue culture infective dose. is possibly involved in DNA precursor synthesis or a regulation of signal transduction. The observation that siRNAs targeting A151R down-regulate the expression of VP72 mRNAs suggests that the protein might also play a direct or indirect role in viral transcription. Dixon et al. [27] and Rodriguez et al. [26] have also suggested that this protein could possibly play a role in ASFV morphogenesis during the later stages of the viral life cycle. The A151R protein contains two cysteine residues in a conserved motif CXXC at amino acid positions 132-135, characteristic of proteins involved in the thioredoxin family pathway [28, 29] . It is suggested that the A151R gene encodes a non-structural protein that interacts with the non-structural protein B119L as part of the redox potential reduction pathway responsible for the formation of the disulfide bonds of E248R protein. The E248R protein is essential for the correct assembly of a mature virions in a reducing environment.
Deletion of the B119L gene has been shown to significantly reduce virus morphogenesis, resulting in the decrease of virus titres and the increased formation of aberrant virions [26] . The results described herein support the hypothesis that the A151R protein might be involved in a crucial step of virus morphogenesis. To our knowledge, this work is the fifth demonstration of the efficacy of siRNA on a double-stranded DNA virus that replicates in the cell cytoplasm. The first three demonstrations were from the same research group working on the orthopoxvirus vaccinia [30, 31, 32] . By targeting the DNA-independent nucleoside triphosphatase gene (D5 protein) with 100 nM of specific siRNA, this research group was able to reduce the replication of vaccinia virus (VACV) by 96% (1.4 log 10 ). Whatever the virus load used for cell infection (MOI from 0.0001 up to 3), the maximum reduction of the virus titre in the earlier studies could not exceed 2 log 10 [30] , compared with our 4 log 10 reduction (99.99% reduction) using an MOI of 0.1. In another study by this group, the VACV G7L gene was also targeted. It is an early gene and its product is required for virus morphogenesis, just as A151R protein is required for ASFV. At 24 h posttransfection of siRNAs against G7L, the VACV titre produced after infection with 0.1 MOI and incubation over 24 h was reduced by 99% [32] , which is 1-2 log 10 values less than the reduction achieved in our work. By contrast, a fourth study targeting the A6R gene of Monkeypox virus showed an almost complete inhibition of virus replication when specific siRNAs were delivered at 40 nM, 18 h before infection at 0.1 MOI [33] . The antiviral therapeutic effect of siRNAs against 0.0001 MOI of VACV at 1, 8 and 24 h post-infection showed a reduction of VACV replication of 92.0%, 72.3% and 74.2% respectively [30] . In the present study, we could only successfully reduce CPE (by 70%) and titre (reduction of 2.5 log 10 ) when the siRNAs were delivered 1 h postinfection. At 24 h post-infection, the therapeutic effects of siRNAs were minimal; however, it must be stressed that our virus load for the infection was 100× higher and the incubation period 1 day longer. In a previous work carried out on morbilliviruses, we also showed that an efficient therapeutic effect from 24 h up to 144 h postinfection could be obtained when reducing the virus load from 0.1 to 0.001 MOI [23] . In conclusion, we provide evidence that the siRNAs identified in this study have excellent efficacy compared with previous works on orthopoxviruses; however, none of these siRNAs could completely inhibit the replication of ASFV, in contrast to our results achieved on another virus, a negativestrand RNA morbillivirus [23] . This might result from the finding that mRNA are less accessible to siRNAs in ASFV viral factories, or that the accumulation of mRNA overwhelms the siRNA production in the cell cytoplasm; however, it could also result from the lack of accessibility of the mRNA targeted region as mentioned by different authors [34] [35] [36] . A rapid analysis of the secondary structure of A151R and VP72 mRNAs using a bioinformatics tool (Rensselaer Polytechnic Institute, Troy, NY, USA) predicted a higher percentage of accessibility (83%) for siRNA-A151R_2 and siRNA-A151R_3 compared with the siRNA-VP72_8 and siRNA-A151R_1 (62%). The combined delivery of multiple siRNAs targeting A151R and VP72 genes did not significantly improve the overall control on the virus replication; however, the benefit from the use of combined siRNAs in previous studies depended on the virus used. In some cases it was improved [37] and in others it was not [38, 39] . Another reason for this discrepancy could be the saturation of RISC by the delivery of high concentrations of multiple siRNAs [39] . In order to clarify this hypothesis, we intend to generate Vero cells constitutively expressing active siRNAs to avoid the need to transfect high doses of siRNA into the cell cytoplasm. By generating cell cultures constitutively expressing the siRNAs, the problem of cell toxicity could be avoided, possibly resulting in the increased inhibition of virus replication.
Compared with other antiviral molecules tested so far on ASFV, our siRNA provide similar inhibition. For example, the antitumoural drug lauryl gallate used at 10 µM reduced the virus replication by a factor of 3-5 log 10 [40] . Similar to our observations with siRNA, the administration of the drug 24 h after the infection did not significantly control the ASFV replication. This demonstrates that the therapeutic indication of both approaches is limited at present, but that preventive application in case of emergency is still valuable, especially when considering there is no vaccine against this highly fatal disease of swine. One of the advantages of the use of siRNA over the use of alternative antiviral drugs is their tight target specificity and minimal side effects. By contrast, it has been shown that a single mismatch can abolish the interference. Therefore, the efficacy of siRNAs is greatly influenced by the genetic variation within the target sequence. To asses the genetic diversity within the A151R gene, the sequences of the siRNAs were compared with that of several ASFV field isolates. Significant variations were found for some of the siRNA described here. To limit the risk of mismatch, siRNA can be used in combination to target different regions of interest [37, [41] [42] [43] . In our study, the combination of different siRNAs did not improve or reduce the inhibition of ASFV replication; therefore, such a combination could be safely used in our case in order to limit the risk of mismatch or virus escape mutant. For example, the combined use of siRNAs targeting the three active positions of A151R gene, in addition to the following sequences G C C A G G A A G A A
C T T A A A G G, C T T C A G T C G G T C C T C A T A T, C T A A A G C C G G T C C T T G T A T, G C T T A T A G A G T G C A T C T A T and G C T T A T A G A G T G C A T T G A T,
where mutated nucleotides are shown in bold, would cover the genetic variation of 85% of the viruses for which the A151R gene sequences are currently known.
